Table 2.
Factors associated with STE value≥6.5 and STE value≥10.3.
| Variable | Univariate analysis for STE≥ 6.5 | Univariate analysis for STE≥ 10.3 | ||
|---|---|---|---|---|
| OR (95% CI) | P Value | OR (95% CI) | P Value | |
| Demograohics | ||||
| Age | 1.03 (0.98-1.09) | 0.23 | 1.02 (0.94-1.10) | 0.71 |
| Gender | 1.18 (0.30-4.54) | 0.81 | 0.49 (0.08-3.90) | 0.44 |
| Height | 0.93 (0.85-1.00) | 0.07 | 0.94 (0.84-1.05) | 0.24 |
| Weight | 1.02 (0.97-1.07) | 0.53 | 1.07 (0.99-1.17) | 0.09 |
| BMI † | 1.20 (1.00-1.49) | 0.07 | 1.42 (1.11-1.98) | 0.01 |
| BMI<23 (Underweight and Normal) | 0.41 (0.09-1.65) | 0.22 | 0.00 (NA-lnf) | 0.99 |
| 23≤BMI<27.5 (Overweight) | 1.25 (0.41-3.84) | 0.69 | 0.70 (0.12-4.16) | 0.69 |
| 27.5≤BMI<32.5 (General obesity) | 2.30 (0.57-11.67) | 0.26 | 4.75 (0.76-30.18) | 0.08 |
| Lifestyles | ||||
| Smoking status | 1.64 (0.53-5.38) | 0.40 | 0.28 (0.01-1.95) | 0.27 |
| Drinking status | 1.54 (0.48-5.36) | 0.48 | 0.38 (0.02-2.60) | 0.39 |
| Psoriasis-related information | ||||
| Age of onset | 0.99 (0.92-1.05) | 0.63 | 1.02 (0.93-1.13) | 0.66 |
| Duration of psoriasis | 1.08 (1.01-1.17) | 0.04 | 1.00 (0.90-1.11) | 1.00 |
| PASI | 1.01 (0.94-1.09) | 0.78 | 1.00 (0.87-1.10) | 0.97 |
| BSA | 1.01 (0.98-1.05) | 0.56 | 1.01 (0.95-1.05) | 0.72 |
| PsA | 0.69 (0.22-2.14) | 0.52 | 1.56 (0.26-9.23) | 0.61 |
| Prior treatment | ||||
| Methotrexate | 2.49 (0.82-7.96) | 0.11 | 1.83 (0.32-14.17) | 0.51 |
| Acitrenin | 1.87 (0.61-6.15) | 0.28 | 0.71 (0.09-4.03) | 0.71 |
| Phototherapy | 1.75 (0.57-5.56) | 0.33 | 0.60 (0.08-3.37) | 0.57 |
| Current therapy | ||||
| Anti-IL ‡ | 0.61 (0.19-1.83) | 0.38 | 0.42 (0.05-2.37) | 0.34 |
| Anti-TNF § | 1.70 (0.50-6.37) | 0.41 | 1.27 (0.16-7.37) | 0.80 |
| Methotrexate | 1.12 (0.28-4.96) | 0.87 | 2.37 (0.29-14.58) | 0.36 |
| The duration of current treatment | 0.62 (0.21-1.75) | 0.37 | 0.61 (0.09-3.03) | 0.57 |
| Result of STE | ||||
| The diagnosis of fatty liver | 0.69 (0.18-2.38) | 0.56 | 1.97 (0.28-39.66) | 0.55 |
| Baseline STE value | 2.60 (1.37-6.30) | 0.02 | 1.44 (1.04-2.15) | 0.04 |
| Baseline laboratory examinations | ||||
| Alanine aminotransferase | 1.02 (1.00-1.05) | 0.14 | 1.00 (0.97-1.03) | 0.76 |
| Aspartate aminotransferase | 1.03 (0.99-1.08) | 0.22 | 1.02 (0.96-1.06) | 0.46 |
| Albumin | 0.87 (0.67-1.10) | 0.26 | 0.98 (0.69-1.45) | 0.92 |
| Low Density Lipoprotein | 1.44 (0.73-2.98) | 0.59 | 0.64 (0.23-1.72) | 0.37 |
| High Density Lipoprotein | 1.16 (0.22-6.33) | 0.86 | 0.23 (0.01-3.29) | 0.35 |
| Total cholesterol | 1.16 (0.67-2.08) | 0.59 | 0.66 (0.26-1.53) | 0.35 |
| Triglyceride | 0.93 (0.63-1.30) | 0.65 | 0.94 (0.43-1.44) | 0.83 |
| Uric acid | 1.00 (1.00-1.01) | 0.63 | 1.00 (0.99-1.01) | 0.60 |
| γ-glutamyl transpeptadase | 1.01 (1.00-1.03) | 0.17 | 0.97 (0.89-1.01) | 0.29 |
| Glucose | 1.27 (0.51-3.33) | 0.60 | 1.22 (0.29-4.57) | 0.77 |
| Hemoglobin | 1.01 (0.97-1.04) | 0.62 | 0.97 (0.92-1.01) | 0.15 |
| Platelets | 1.00 (0.99-1.01) | 0.48 | 1.00 (0.99-1.02) | 0.78 |
| White blood cells | 1.17 (0.87-1.61) | 0.32 | 0.72 (0.39-1.18) | 0.24 |
†The BMI classification is according to the suggestions for Chinese population from WHO. ‡Anti-interleukin inhibitors included secukinumab (25 patients), ixekizumab (1 patient), guselkumab (1 patient). §Anti-TNFi included adalimumab (14 patients), Etanercept (1 patient). BMI, body mass index; BSA, body surface area; CI, confidence interval; IL, interleukin; MTX, methotrexate; OR, odds ratio; PASI, Psoriasis Area Severity Index; PsA, psoriatic arthritis; TNF, tumor necrosis factor; STE, sound touch elastography.
The bold values are for P values <0.1.